CONTACT US
Home > Inhibitors/Agonists> > Celivarone free base
401925-43-7-Celivarone free base Celivarone free base

Celivarone free base

For research use only. Not for therapeutic Use.

  • CAT Number: I024356
  • CAS Number: 401925-43-7
  • Molecular Formula: C34H47NO4
  • Molecular Weight: 533.753
  • Purity: 98%
Inquiry Now
Related Small Molecules: Bis-PEG1-NHS ester     ISRIB     Anti-Mouse PD-1 Antibody (RMP1-14)    

Celivarone , also known as SSR149744, is a benzofuran derivative with a multifactorial mode of action including class IV Vaughan Williams’ electrophysiological as well as anti-adrenergic properties. Celivarone exhibits effective anti-arrhythmic properties in several ventricular ischemia- or reperfusioninduced arrhythmia models as well as in in vitro and in vivo atrial fibrillation (AF) models. Celivarone shows anti-arrhythmic activities by suppressing reperfusion-induced arrhythmias (i.v. and oral routes) and reducing the early mortality due to myocardial infarction (oral route) in rats models.


Catalog Number I024356
CAS Number 401925-43-7
Synonyms

SSR149744C; SSR-149744C SSR 149744C; Celivarone

Molecular Formula C34H47NO4
Purity 98%
Solubility Soluble in DMSO
Appearance Solid powder
Storage Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
IUPAC Name 5-Benzofurancarboxylic acid, 2-butyl-3-(4-(3-(dibutylamino)propyl)benzoyl)-, 1-methylethyl ester
InChI InChI=1S/C34H47NO4/c1-6-9-14-31-32(29-24-28(19-20-30(29)39-31)34(37)38-25(4)5)33(36)27-17-15-26(16-18-27)13-12-23-35(21-10-7-2)22-11-8-3/h15-20,24-25H,6-14,21-23H2,1-5H3
InChIKey ZCENNVQCOZQSGH-UHFFFAOYSA-N
SMILES O=C(C1=CC=C(OC(CCCC)=C2C(C3=CC=C(CCCN(CCCC)CCCC)C=C3)=O)C2=C1)OC(C)C
Reference

1: Khitri AR, Aliot EM, Capucci A, Connolly SJ, Crijns H, Hohnloser SH, Kulakowski P, Roy D, Radzik D, Kowey PR. Celivarone for maintenance of sinus rhythm and conversion of atrial fibrillation/flutter. J Cardiovasc Electrophysiol. 2012 May;23(5):462-72. doi: 10.1111/j.1540-8167.2011.02234.x. Epub 2011 Dec 15. PubMed PMID: 22171925.
2: Gojkovic O, Aliot EM, Capucci A, Connolly SJ, Crijns H, Hohnloser SH, Kulakowski P, Roy D, Radzik D, Singh BN, Kowey PR. Celivarone in patients with an implantable cardioverter-defibrillator: adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverter-defibrillator interventions. Heart Rhythm. 2012 Feb;9(2):217-224.e2. doi: 10.1016/j.hrthm.2011.09.073. Epub 2011 Oct 4. PubMed PMID: 21978965.
3: Whitehead DM, Hartmann S, Ilyas T, Taylor KR, Kohler AD, Ellames GJ. A convenient method to produce [(14) C]carbon monoxide and its application to the radiosynthesis of [carboxyl-(14) C]celivarone, [carboxyl-(14) C]SSR149744. J Labelled Comp Radiopharm. 2013 Feb;56(2):36-41. doi: 10.1002/jlcr.3009. Epub 2013 Jan 22. PubMed PMID: 24285280.
4: Kowey PR, Crijns HJ, Aliot EM, Capucci A, Kulakowski P, Radzik D, Roy D, Connolly SJ, Hohnloser SH; ALPHEE Study Investigators. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study. Circulation. 2011 Dec 13;124(24):2649-60. doi: 10.1161/CIRCULATIONAHA.111.072561. Epub 2011 Nov 14. PubMed PMID: 22082672.
5: Bunch TJ, Anderson JL. Adjuvant antiarrhythmic therapy in patients with implantable cardioverter defibrillators. Am J Cardiovasc Drugs. 2014 Apr;14(2):89-100. doi: 10.1007/s40256-013-0056-x. Review. PubMed PMID: 24288157.
6: Naccarelli GV, Wolbrette DL, Samii S, Banchs JE, Penny-Peterson E, Gonzalez MD. New antiarrhythmic treatment of atrial fibrillation. Expert Rev Cardiovasc Ther. 2007 Jul;5(4):707-14. Review. PubMed PMID: 17605649.
7: Han TS, Williams GR, Vanderpump MP. Benzofuran derivatives and the thyroid. Clin Endocrinol (Oxf). 2009 Jan;70(1):2-13. doi: 10.1111/j.1365-2265.2008.03350.x. Epub 2008 Aug 22. Review. PubMed PMID: 18727707.
8: Gramley F, Himmrich E, Mollnau H, Theis C, Hammwohner M, Goette A. Recent advances in the pharmacological treatment of cardiac arrythmias. Drugs Today (Barc). 2009 Nov;45(11):807-24. doi: 10.13581/dot.2009.45.11.1412574. Review. Erratum in: Drugs Today (Barc). 2010 Jan;46(1):69. PubMed PMID: 20126673.
9: Mason PK, DiMarco JP. New pharmacological agents for arrhythmias. Circ Arrhythm Electrophysiol. 2009 Oct;2(5):588-97. doi: 10.1161/CIRCEP.109.884429. Review. PubMed PMID: 19843928.
10: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 May;30(4):313-31. PubMed PMID: 18773127.
11: Verma A. Alternatives to amiodarone: search for the Holy Grail. Europace. 2009 Apr;11(4):402-4. doi: 10.1093/europace/eup042. Epub 2009 Feb 17. PubMed PMID: 19223364.
12: Arya A, Silberbauer J, Teichman SL, Milner P, Sulke N, Camm AJ. A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology. Europace. 2009 Apr;11(4):458-64. doi: 10.1093/europace/eun384. Epub 2009 Jan 26. PubMed PMID: 19174378; PubMed Central PMCID: PMC2659603.
13: Gautier P, Serre M, Cosnier-Pucheu S, Djandjighian L, Roccon A, Herbert JM, Nisato D. In vivo and in vitro antiarrhythmic effects of SSR149744C in animal models of atrial fibrillation and ventricular arrhythmias. J Cardiovasc Pharmacol. 2005 Feb;45(2):125-35. PubMed PMID: 15654261.
14: Gautier P, Guillemare E, Djandjighian L, Marion A, Planchenault J, Bernhart C, Herbert JM, Nisato D. In vivo and in vitro characterization of the novel antiarrhythmic agent SSR149744C: electrophysiological, anti-adrenergic, and anti-angiotensin II effects. J Cardiovasc Pharmacol. 2004 Aug;44(2):244-57. PubMed PMID: 15243307.

Request a Quote